Hepatitis B surface antigen reduction by switching from long‐term nucleoside/nucleotide analogue administration to pegylated interferon

• Published in: Journal of viral hepatitis Vol. 24; no. 8; pp. 672 - 678
• Main Authors: Tamaki, N., Kurosaki, M., Kusakabe, A., Orito, E., Joko, K., Kojima, Y., Kimura, H., Uchida, Y., Hasebe, C., Asahina, Y., Izumi, N.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.08.2017
• Subjects: Adult; Aged; Alanine; Alanine transaminase; Antigens; Antiviral Agents - administration & dosage; Case-Control Studies; chronic hepatitis B; Deoxyribonucleic acid; DNA; DNA, Viral - blood; Drug Substitution - methods; Female; HBsAg; Hepatitis; Hepatitis B; Hepatitis B e antigen; Hepatitis B e Antigens - blood; Hepatitis B surface antigen; Hepatitis B Surface Antigens - blood; Hepatitis B, Chronic - drug therapy; Humans; Interferon; Interferon-alpha - administration & dosage; Male; Middle Aged; Nucleoside analogs; Nucleosides - administration & dosage; Nucleotide analogs; Nucleotides - administration & dosage; PEG‐IFN; Polyethylene glycol; Polyethylene Glycols - administration & dosage; Recombinant Proteins - administration & dosage; Retrospective Studies; sequential therapy; Seroconversion; Treatment Outcome; chronic hepatitis B; sequential therapy; PEG-IFN; HBsAg
• ISSN: 1352-0504; 1365-2893
• DOI: 10.1111/jvh.12691

Summary Hepatitis B surface antigen (HBsAg) reduction during nucleoside/nucleotide analogue (NA) therapy is slow and an alternative strategy for patients receiving ongoing NA to facilitate HBsAg reduction is required. We investigated whether switching to pegylated interferon (PEG‐IFN) after long‐term NA administration enhances HBsAg reduction. Forty‐nine patients who switched from long‐term NA to 48 weeks of PEG‐IFN alfa‐2a were studied. The mean duration of previous NA was 48 months (sequential group). A total of 147 patients who continued NA and matched for baseline characteristics were analysed for comparison (NA continuation group). The treatment response was defined as HBsAg reduction ≥1.0 logIU/mL at the end of PEG‐IFN. HBsAg reduction at week 48 was 0.81±1.1 logIU/mL in the sequential group, which was significantly higher than that in the NA continuation group (0.11±0.3 logIU/mL, P < .001). The treatment response was achieved in 29% and 2% of the sequential group and NA continuation group (P < .001), and the odds ratio of sequential therapy for the treatment response was 19 compared with the NA continuation (P < .001). In patients tested positive for hepatitis B e antigen (HBeAg), HBeAg seroconversion was higher in the sequential group (44% vs 8%, P < .001). In HBeAg‐negative patients, only patients in the sequential group achieved HBsAg loss. No patient needed to resume NA administration because of HBV DNA increase accompanied by alanine aminotransferase flares. In summary, sequential therapy with PEG‐IFN after long‐term NA enhances the reduction of HBsAg and may represent a treatment option to promote HBsAg loss.